Dermata Therapeutics Inc. (DRMA)
NASDAQ: DRMA
· Real-Time Price · USD
5.90
0.09 (1.55%)
At close: Aug 15, 2025, 3:59 PM
5.98
1.36%
After-hours: Aug 15, 2025, 04:00 PM EDT
Dermata Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -1.7M | -2.3M | -3.15M | -3.17M | -2.83M | -3.13M | -2.13M | -1.72M | -1.7M | -2.24M | -1.67M | -2.42M | -2.73M | -2.79M | -2.55M | -1.71M | -1.33M | -2.3M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 39.23K | 37.19K | 29.82K | 20.99K | 19.61K | 587.23K | 128.47K | 131.18K | 131.18K | 131.26K | 220.89K | 234.98K | 261.57K | 212.88K | 488.72K | 142.66K | 113.99K | 1.16M |
Other Working Capital | n/a | 230.27K | 305.7K | 103.81K | 279.81K | -113.94K | 466.63K | -220.27K | -215.09K | 463.08K | -389.78K | -246.6K | 682.9K | -181.56K | 514.85K | -528.5K | -78.7K | -29.07K |
Other Non-Cash Items | -1.03M | n/a | n/a | 259.36K | n/a | n/a | n/a | n/a | 131.18K | n/a | 220.89K | 234.98K | -53.42K | 212.88K | 488.72K | 156.00 | 78.00 | 13.89K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | 332.33K | 207.51K | -526.12K | 683.54K | -157.43K | 858.2K | -183.59K | -270.18K | 459.25K | -376.82K | -371.67K | 629.49K | -34.58K | 260.23K | -639.94K | 314.51K | 354.75K |
Operating Cash Flow | -2.69M | -1.93M | -2.91M | -3.42M | -2.13M | -2.7M | -1.15M | -1.77M | -1.84M | -1.65M | -1.83M | -2.56M | -1.84M | -2.61M | -1.8M | -2.21M | -903.21K | -776.22K |
Capital Expenditures | n/a | -4 | 4.00 | -3 | 3.00 | n/a | 5.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.01M |
Common Stock Repurchased | n/a | n/a | n/a | 828.00 | -828 | n/a | n/a | -35.42 | n/a | -40 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -547.86K | n/a | 941.00 | 70.17K | -70K | n/a | n/a | n/a | 34.00 | 193.00 | 4.27B | 200.00 | 87.00 | n/a | n/a | n/a | n/a | 570K |
Financial Cash Flow | -547.86K | 8.49M | -68.57K | 4.62M | 2.34M | n/a | 1.95M | -35.42K | 1.51M | 4.18M | 4.27B | 200.00 | 4.28M | n/a | -626 | 14.39M | n/a | 1.58M |
Net Cash Flow | -3.24M | 6.56M | -2.98M | 1.2M | 213.42K | -2.7M | 806.65K | -1.81M | -328.23K | 2.53M | -1.83M | -2.56M | 2.44M | -2.61M | -1.8M | 12.18M | -903.21K | 800.01K |
Free Cash Flow | -2.69M | -1.93M | -2.91M | -3.42M | -2.13M | -2.7M | -1.15M | -1.77M | -1.84M | -1.65M | -1.83M | -2.56M | -1.84M | -2.61M | -1.8M | -2.21M | -903.21K | -776.22K |